Skip to content

Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia

Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia: a Double Blind Sham-controlled Randomised Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02175251
Acronym
rTMS
Enrollment
33
Registered
2014-06-26
Start date
2014-02-28
Completion date
2017-09-29
Last updated
2023-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

rTMS, Schizophrenia, high frequency rTMS, low frequency rTMS, AHRS, SAPS SANS PANSS, GAF, UKU

Brief summary

Auditory Hallucinations (AH) are experienced by 50 to 70% of subjects with schizophrenia. Almost a quarter of patients are medication resistant to such symptoms. The application of rTMS at low frequency in the left temporoparietal cortex reduces AH. A pilot study reported successful treatment of AH with high frequency rTMS. rTMS (20Hz) should be a shorter and an easier treatment for out-patients with schizophrenia compared to low stimulation treatment.

Detailed description

90 schizophrenia patients Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV-TR) criteria with persistent Auditory Hallucinations (AH) resistant to antipsychotic treatments will be recruited. A double blind sham-controlled randomized parallel study comparing three groups treated 10 session in 5 days with high frequency (20 Hz), low frequency (1Hz) and sham-controlled condition rTMS. They will be followed 3 month and evaluated using Auditive Hallucination Rating Scale (AHRS), Scale for the Assessment of Positive Symptoms Scores (SAPS), Scale for the Assessment of Negative Symptoms Scores (SANS) and Positive And Negative Symptom Scale (PANSS) global score and Global Assessment of Functioning (GAF) score.

Interventions

PROCEDURElow frequency (1Hz)

10 session in 5 days with low frequency (1Hz)

PROCEDURESham Comparator

10 session in 5 days with sham-controlled

PROCEDUREhigh frequency (20Hz)

10 session in 5 days with high frequency (20 Hz)

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with schizophrenia DSM IV-TR criteria and persistent AH resistant to antipsychotic treatments.

Exclusion criteria

* Left handed patients lateralizes * rTMS contraindications

Design outcomes

Primary

MeasureTime frameDescription
To evaluate the efficiency of high frequency (20Hz) repetitive Transcranial Magnetic Stimulation (rTMS) to the left temporoparietal cortex compared to sham controlled condition rTMS in term on Auditory Hallucinations reduction.5 dayAuditory Hallucinations improvement at 5-day was evaluate with AHRS (Auditory Hallucination Rating Scale) score

Secondary

MeasureTime frameDescription
To compare the efficiency of low frequency (1Hz) to sham-controlled condition repetitive Transcranial Magnetic Stimulation (rTMS) in term of Auditory Hallucination reduction.5 daysAuditory Hallucinations improvement evaluated with Auditory Hallucination Rating Scale (AHRS)
To compare the efficiency of high frequency to low frequency (1Hz) in term of Auditory Hallucination reduction.5 daysAuditory Hallucinations improvement evaluated with Auditory Hallucination Rating Scale (AHRS)
To compare the maintenance of therapeutic effect for one month of high frequency to low frequency (1Hz) in term of Auditory Hallucination reduction.1 monthAuditory Hallucinations improvement evaluated with Auditory Hallucination Rating Scale (AHRS)
To evaluate the maintenance of therapeutic effect of high frequency compared to sham controlled condition for 15 days 1 month, 2 months and 3 months15 days 1 month, 2 months and 3 months
To compare the side effects of each of the active treatmentat Inclusion and 5 dayTolerance assessed with the UDVALG of KLINISKE UNDERSOGELSER scale (UKU )

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026